Forte Biosciences (FBRX) Net Income towards Common Stockholders (QoQ) (2016 - 2026)
Forte Biosciences (FBRX) Net Income towards Common Stockholders (QoQ) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Forte Biosciences | 1.37 Bn | 1.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.07% |
| Dec 31, 2025 | 31.23% |
| Sep 30, 2025 | -45.44% |
| Jun 30, 2025 | -57.19% |
| Mar 31, 2025 | -110.66% |
| Dec 31, 2024 | 14.15% |
| Sep 30, 2024 | 32.61% |
| Jun 30, 2024 | -64.03% |
| Mar 31, 2024 | -22.17% |
| Dec 31, 2023 | 37.28% |
| Sep 30, 2023 | -12.06% |
| Jun 30, 2023 | -31.71% |
| Mar 31, 2023 | -38.39% |
| Dec 31, 2022 | -42.12% |
| Sep 30, 2022 | -8.74% |
| Jun 30, 2022 | -14.90% |
| Mar 31, 2022 | 78.13% |
| Dec 31, 2021 | -47.51% |
| Sep 30, 2021 | 69.80% |
| Jun 30, 2021 | 0.67% |